

1. Record Nr.	UNINA9910777388403321
Autore	Cook Michael <1940->
Titolo	Commanding right and forbidding wrong in Islamic thought / / Michael Cook
Pubbl/distr/stampa	Cambridge : , : Cambridge University Press, , 2000
ISBN	0-511-08247-9 1-107-11826-3 1-280-16233-3 0-511-11809-0 0-511-01868-1 0-511-15589-1 0-511-30401-3 0-511-49745-8 0-511-04880-7
Descrizione fisica	1 online resource (xvii, 702 pages) : digital, PDF file(s)
Disciplina	297.5
Soggetti	Islamic ethics Religious life - Islam Islam - Doctrines
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references (p. [604]-[660] and index.
Nota di contenuto	pt. 1. Introductory -- pt. 2. The Hanbalites -- pt. 3. The Mu'tazilites and Shi'ites -- pt. 4. Other sects and schools -- pt. 5. Beyond classical Islam.
Sommario/riassunto	What kind of duty do we have to try to stop other people doing wrong? The question is intelligible in just about any culture, but few of them seek to answer it in a rigorous fashion. The most striking exception is found in the Islamic tradition, where 'commanding right' and 'forbidding wrong' is a central moral tenet already mentioned in the Koran. As an historian of Islam whose research has ranged widely over space and time, Michael Cook is well placed to interpret this complex subject. His book represents the first sustained attempt to map the history of Islamic reflection on this obligation. It covers the origins of

Muslim thinking about 'forbidding wrong', the relevant doctrinal developments over the centuries, and its significance in Sunni and Shi'ite thought today. In this way the book contributes to the understanding of Islamic thought, its relevance to contemporary Islamic politics and ideology, and raises fundamental questions for the comparative study of ethics.

2. Record Nr.	UNINA9910261141903321
Autore	Abedon Stephen T
Titolo	Phage Therapy: Past; Present and Future
Pubbl/distr/stampa	Frontiers Media SA, 2017
Descrizione fisica	1 online resource (392 p.)
Collana	Frontiers Research Topics
Soggetti	Microbiology (non-medical)
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (<i>Bacillus anthracis</i>) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d'Herelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of

multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.
